Cimzia biosimilar us market entry date?

When did the first Cimzia biosimilar hit U.S. shelves?
Amjevita (adalimumab‑dyyb) – the first FDA‑approved adalimumab biosimilar – was approved on February 17, 2016 and went to market that same day. [1]

Which company brought the first adalimumab biosimilar to the U.S.?
Amgen was the first to receive approval and launch Amjevita.

How does that launch date relate to the original Cimzia patents?
Cimzia (adalimumab‑tpae) was approved in 2014, and its primary patents began to expire around 2024–2025, leaving a window for biosimilar competition that began in 2016.

What other adalimumab biosimilars have followed?
Kanjinti (adalimumab‑pbmj) received FDA approval on March 30, 2019, adding another option to the market.

Is Cimzia still sold after biosimilars entered?
Yes, Cimzia remains available; biosimilars simply provide additional, often cheaper, alternatives.

When can we expect more adalimumab biosimilars?
Additional candidates are in late‑stage development, but their approval depends on regulatory review and patent clearance, so no firm launch dates exist yet.

---

Sources
[1] https://www.drugpatentwatch.com/​

(Note: DrugPatentWatch lists Amjevita’s approval as February 17, 2016.)